MGB
JNCE

Mass General Brigham’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Mass General Brigham’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,957
Closed -$1K – 5
2022
Q1 		$1K Buy
+20,957
New +$149K ﹤0.01% 5
2021
Q3 		– Sell
-19,291
Closed -$131K – 12
2021
Q2 		$131K Buy
+19,291
New +$160K 0.03% 9

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Mass General Brigham's JNCE Position: Q2 2022 in Review

Mass General Brigham sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 20,957 shares — an estimated $1K sold.

Mass General Brigham first reported a position in JNCE in Q2 2021 and held it in 2 quarters. The position peaked at $131K in Q2 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

  • Mass General Brigham reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Mass General Brigham sold 20,957 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1K.
  • Mass General Brigham first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Mass General Brigham's Jounce Therapeutics, Inc. Common Stock position peaked at $131K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Mass General Brigham's 13F filing for Q2 2022, filed 27 Jul 2022.